Trial in progress: A phase 1b single-arm, open-label, study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in acute myeloid leukemia patients in complete response with measurable residual disease

Venclexta (venetoclax) - Roche, AbbVie

azacitidine - Generic mfg.

emavusertib (CA-4948) - Curis, Dr. Reddy’s

https://www.abstractsonline.com/pp8/#!/20272/presentation/11617

Reinhard von Roemeling 1; Adolfo De La Fuente 2; Claudio Cerchione 3; Sebastian Scholl 4; Nitika Fnu 1; Jan Moritz Middeke 5; Gaurav S. Choudhary 1; Maria Lamar 1; Steven Angelides 1; Uwe Platzbecker6

Mar 6, 2024